Morgan Stanley Reiterates Equal-Weight Rating on Hospira

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Hospira

. Morgan Stanley noted, “November IMS sales were $118 MM, down 4% Y/Y and down 2% MoM vs. down 6% Y/Y and up 2% MoM in October suggesting stability in US SIP. Core business weekly average sales were +4.6% M/M versus +1.1% in October consistent with some progress in 4Q. However, stock performance remains more tied to 1H13 Rocky Mount re-inspection and device remediation progress.” Hospira closed on Friday at $30.69.